Introduction Innovations in anti-neoplastic treatments have amplified the number of long-term survivors. Even with novel malignancy therapies, anthracyclines are the foundation of cancer treatment, especially in hematologic malignancies, sarcomas, and breast cancer. Heart failure (HF) has been described in up to 10% of tumor survivors, and the progression to end-stage HF in 2% to 3%. According to estimations grounded on retrospective registry data, such as United Network for Organ Sharing (UNOS) or Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) […]